1
Fujita Takashi, Wada Kunio, Oguchi Minoru, Yanagisawa Hiroaki, Fujimoto Koichi, Fujiwara Toshihiko, Horikoshi Hiroyoshi, Yoshioka Takao: Benzimidazole derivatives, their preparation and their therapeutic use. Sankyo, December 4, 1996: EP0745600-A1 (42 worldwide citation)

Compounds of formula (I): Äin which: X represents an optionally substituted benzimidazole group; Y represents an oxygen or sulphur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2,4-dioxo-oxazolidin-5-ylmethyl, 3,5-dioxooxadiazolidin-2-ylmethyl or N-hydr ...


2
Fujita Takashi, Yoshioka Takao, Yanagisawa Hiroaki, Fujiwara Toshihiko, Horikoshi Hiroyoshi, Oguchi Minoru, Wada Kunio, Fujimoto Koichi: Thiazolidine and oxazolidine derivatives, their preparation and their medical use.. Sankyo, October 25, 1995: EP0678511-A2 (30 worldwide citation)

Compounds of formula (I): [in which: R and R are each hydrogen or alkyl, or together a group of formula -(CH2)k- in which k is an integer; R is hydrogen, alkyl, alkoxy, halogen or hydroxy; A and B are each hydrogen, alkyl, aralkyl, aliphatic carboxylic acyl, aryl-substituted aliphatic carboxylic acy ...


3
Fujita Takashi C O Sankyo Comp, Yoshioka Takao C O Sankyo Comp, Yoshioka Shinji C O Sankyo Com, Fujiwara Toshihiko C O Sankyo, Horikoshi Hiroyoshi C O Sankyo: Oxazolidine derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses.. Sankyo, April 6, 1994: EP0590793-A1 (26 worldwide citation)

Compounds of formula (I): wherein: R is an alkyl group; X is oxygen or sulphur; Y is hydrogen atom or -A-COOH, in which A is an alkylene group; Ar is aryl or substituted aryl group; and pharmaceutically acceptable salts and esters thereof, have use in the treatment or prophylaxis of diabetes, obesit ...


4
Fujita Takashi C O Sankyo Comp, Fujimoto Koichi C O Sankyo Com, Yoshioka Takao C O Sankyo Comp, Yanagisawa Hiroaki C O Sankyo, Fujiwara Toshihiko C O Sankyo, Horikoshi Hiroyoshi C O Sankyo, Oguchi Minoru C O Sankyo Compa, Wada Kunio C O Sankyo Company: Heterocyclic compounds having anti-diabetic activity, their preparation and their use.. Sankyo, October 11, 1995: EP0676398-A2 (26 worldwide citation)

Compounds of formula (I): [wherein: X represents an unsubstituted or substituted indolyl, indolinyl, azaindolyl, azaindolinyl, imidazopyridyl or imidazopyrimidinyl group; Y represents an oxygen or sulphur atom; Z represents a 2,4-dioxothiazolidin-5-ylidenylmethyl, 2,4-dioxothiazolidin-5-ylmethyl, 2, ...


5
Yanagisawa Hiroaki, Fujita Takashi, Fujimoto Koichi, Yoshioka Takao, Wada Kunio, Oguchi Minoru, Fujiwara Toshihiko, Horikoshi Hiroyoshi: Oxime derivatives, their preparation and their therapeutic use. Sankyo, April 24, 1996: EP0708098-A1 (19 worldwide citation)

Compounds of formula (I) : in which: R is hydrogen or alkyl; R is alkylene; R is hydrogen, alkyl, alkoxy, alkylthio, halogen, nitro group, amino group, monoalkylamino, dialkylamino, aryl, or aralkyl; X is aryl, or aromatic heterocyclic; Y is oxygen, sulfur or a group of formula >N-R, in which R is h ...


6
Fujiwara Toshihiko, Miyamoto Masaaki, Horikoshi Hiroyoshi: Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis. Sankyo, July 16, 1997: EP0783888-A1 (19 worldwide citation)

Compounds of formula (I): Äwhere R, R, R and R are hydrogen or alkyl and R is hydrogen, alkyl or various organic groupsÜ are effective against osteoporosis at doses at which they also effectively control diabetes.


7
Fujiwara Toshihiko, Ushiyama Shigeru, Kimura Tomio: New antidiabetic pharmaceutical composition. Sankyo, May 8, 2003: JP2003-128551 (19 worldwide citation)

PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for prophylaxis or therapy of diabetes.SOLUTION: This pharmaceutical composition for the prophylaxis or therapy of the diabetes comprises a compound having general formula (I) [wherein A denotes benzene, pyridine, pyridazine, pyrimidine, ...


8
Tsujita Yoshio, Fujiwara Toshihiko, Sada Toshio, Maeda Naoyuki: Pharmaceutical compositions comprising cs-866 and insulin resistance improving agents and their use for the treatment of arteriosclerosis and xanthoma. Sankyo, July 21, 1999: EP0930076-A1 (16 worldwide citation)

A pharmaceutical composition comprising as its active ingredients one or more drugs selected from the group consisting of angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors, and one or more insulin resistance improving agents exhibits excellent arteriosclerotic progress ...


9
Horikoshi Hiroyoshi, Fujiwara Toshihiko, Yoshioka Shinji, Nishino Hiroshi, Koike Hiroyuki, Yoshioka Takao: Thiazolidine derivatives having anti-hypertensive activity and their therapeutic use.. Sankyo, July 31, 1991: EP0439321-A2 (15 worldwide citation)

Thiazolidine derivatives of formula (I): (in which: R, R, R, R are each hydrogen or alkyl; and R is hydrogen, aliphatic acyl, alkoxycarbonyl, or arylcarbonyl) and pharmaceutically acceptable salts thereof are anti-hypertensive agents and are useful in the treatment of obesity-related hypertension an ...


10
Fujiwara Toshihiko, Iwasaki Koichi, Horikoshi Hiroyoshi: Composition for use in the treatment and prevention of hyperuricemia. Sankyo, June 2, 1999: EP0919232-A1 (14 worldwide citation)

Insulin sensitivity enhancers, such as troglitazone, have the ability to treat and/or prevent hyperuricemia and may thus be used for the therapy or prophylaxis of such diseases as gout, urinary calculus, hyperuricemic nephropathy and Lesch-Nyhan syndrome.